Form 4 for ARTV Artiva Biotherapeutics, Inc.
Accepted 2025-11-17 00:00:00 ET · period of report 2025-11-15 · accession 0001193125-25-285004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2025-11-17 | 2025-11-15 | ARTV | Aslan Fred | Pres, CEO, Dir | F - Tax | $3.25 | -6,347 | 350.4K | -2% | -$20.6K |
| T | 2025-11-17 | 2025-11-17 | ARTV | Aslan Fred | Pres, CEO, Dir | S - Sale | $3.38 | -6,375 | 344.0K | -2% | -$21.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-15 | F | D | 6,347 | $3.25 | 350,374 | D | — | — | (F1) Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards. |
| 2 | Common | Common Stock | 2025-11-17 | S | D | 6,375 | $3.38 | 343,999 | D | — | — | (F3) The weighted average sale price for the transaction reported was $3.376, and the range of prices were between $3.19 and $3.53. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |